Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
P/E(ttm) 19.84
XPH's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 19.84 )
Ranked among companies with meaningful P/E(ttm) only.
XPH' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 31.71
Current: 19.84
0
31.71
PE(NRI) 19.84
XPH's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 19.84 )
Ranked among companies with meaningful PE(NRI) only.
XPH' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 31.71
Current: 19.84
0
31.71
P/B 2.13
XPH's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 2.13 )
Ranked among companies with meaningful P/B only.
XPH' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.79
Current: 2.13
0
2.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
XPH's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.64 )
Ranked among companies with meaningful Dividend Yield only.
XPH' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.64
Current: 0.64
0
0.64
Yield on cost (5-Year) 0.64
XPH's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.64 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XPH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.64
Current: 0.64
0
0.64

More Statistics

Short Percentage of Float0.00%
52-Week Range $36.67 - 47.65
Shares Outstanding (Mil)12,000,270.00
» More Articles for XPH

Headlines

Articles On GuruFocus.com
Call Me When You Have A Real Insurance Company! Jan 23 2017 
Buying Underperforming Sectors Yields Results, but Be Careful Jan 23 2017 
Now Is the Time for Deep Value Jan 23 2017 
Investing in the Future of Retail Jan 23 2017 
The Difference Between the Ex-Dividend Date, Record Date and Pay Date Jan 23 2017 
McDonald’s: Focus on Franchise Model Will Drive Growth Jan 23 2017 
AbbVie Increases Price of Humira Jan 23 2017 
Donald Trump and the Dollar Jan 23 2017 
Is a Twitter Turnaround Possible? Jan 23 2017 
Why Chipotle Is a Sell Going Into Earnings Jan 23 2017 

More From Other Websites
A.M. Funds Roundup: Investors Buy Volatility ETFs, Exit Equity ETFs Ahead Of Inauguration, Jan 20 2017
What Lies Ahead for Pharma ETFs? Jan 19 2017
Biotech ETFs: When Will The Pain End? Jan 17 2017
Biotech ETFs Continue To Bleed Jan 12 2017
Trump's First Press Conference Puts These ETFs in Focus Jan 12 2017
Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales Jan 12 2017
The Biggest Loser: Endo International Tumbles 8.6% Jan 11 2017
2 Stocks For a Trump-ed Up Pharma Market Jan 11 2017
Biotech, Pharma ETFs Sink; Trump Promises "Bidding Procedures" Jan 11 2017
Tesaro NDA for ovarian cancer treatment granted priority review Dec 20 2016
It Was a Successful 3Q16 for Horizon Pharma’s Primary Care Dec 20 2016
Mylan's first generic EpiPen launches at less than half the cost of branded version Dec 16 2016
Loss of Patent Protection to Drag Pfizer’s Top Line Dec 14 2016
Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer Dec 12 2016
Express Scripts’ stock rocked by tweets from short seller Andrew Left Dec 09 2016
Biotech & Pharma ETFs to Suffer in 2017 Too? Dec 08 2016
Express Scripts' stock dives after short seller Andrew Left takes aim Dec 08 2016
President-elect Trump’s promise to bring down drug prices sends biotech and pharma ETFs slumping Dec 07 2016
Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares Dec 07 2016
Biotech ETFs: So Much For The Trump Bounce Dec 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK